CLOV Q4 Earnings Beat Estimates, Sales Miss, Membership Rises
Clover Health's fourth-quarter 2024 results continue to benefit from the strength of its strong member retention. Strong revenue outlook bodes well.
Clover Health Investments, Corp. (CLOV) Q4 2024 Earnings Call Transcript
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS Tolf Cormanon - Craig Hallam Operator Ladies and gentlemen, good afternoon and welcome to the Clover Health Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Clover Health Investments, Corp. (CLOV) Tops Q4 Earnings Estimates
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.12 per share a year ago.
Clover Health: Watch Out For Volatility Following Q4 Earnings Results
I remain bullish on Clover Health long-term but prefer to Hold until Q4 2024 earnings for higher conviction before initiating a long position in this stock. I believe the 40% YTD rise and 60% retail ownership increase the risk of profit taking post-earnings, similar to the Q3 panic selloff. On the positive side, the company has recently reported a 27% increase in Medicare Advantage members, surpassing 100,000 lives, with 95% in its 4-Star PPO plan.
Clover Health Investments Is Building A Competitive Moat
Clover Health Investments, Corp. is a healthcare provider focused on providing Medicare Advantage plans to seniors. The company's proprietary AI technology helps drive higher reimbursement rates and lower cost of care. The company is leaning into demographic and consumer preference tailwinds giving it a unique competitive advantage.
Clover Health: Undervalued Turnaround Play With Promising SaaS Potential
Clover Health's revenue rose 8% in Q3 2024, driven by a 7% growth in Medicare Advantage premiums, despite exiting low-margin ACO REACH program. Cost control measures are paying off, with salaries and benefits down 9%, general expenses down 14%, and losses narrowing significantly. Strong cash reserves of $287.9 million and no long-term debt provide a safety net for strategic investments, particularly in the Clover Assistant platform.
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
Recent Earnings Disappointment Could Be An Ideal Buying Opportunity For Clover Health
Clover Health's recent performance shows mixed results, with revenue growth but a significant share price drop, presenting a potential buying opportunity. Operational efficiency is improving, with better adjusted EBITDA and reduced net loss, indicating progress towards profitability. Wall Street remains optimistic, with positive ratings and a potential 46% upside, bolstered by a Medicare Advantage PPO plan upgrade.
Clover Health: Balancing Innovation And Challenges
Clover Health Investments shows financial progress and challenges in 2024, with a focus on innovative Medicare Advantage plans and technology-driven healthcare solutions. The company achieved a 4.0 rating for its PPO plan, indicating improved quality of care and potential for higher CMS reimbursements. Despite a slight membership decline, Clover's financial efficiency has improved, with net income losses decreasing significantly from 2022 to 2024.
Here's Why Clover Health Investments (CLOV) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Clover Health: Buy The Dip, Reap The Rewards
Clover's 32% dip following its Q3 earnings could be an opportunity to accumulate shares. Clover continues to grow its topline and improve its bottom line performance. Clover's latest star rating upgrade to 4 stars for payment year 2026 could help it increase its market share and secure more deals for Counterpart Assistant.
Down -26.32% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround
Clover Health Investments (CLOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
